A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study (the second phase in testing a new drug or combination to see how
effect the drug or combination is) of investigational drugs GSK2256098 and Trametinib.
The purpose of the study is to evaluate the antitumor activity of GSK2256098 and Trametinib
in patients with advanced pancreatic cancer.